MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.ppat.1012627

Медицинская библиотека · PLoS pathogens · 2024

A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.

Ferreira Letícia Tiburcio, Cassiano Gustavo Capatti, Alvarez Luis Carlos Salazar, Okombo John, Calit Juliana, Fontinha Diana, Gil-Iturbe Eva, Coyle Rachael, Andrade Carolina Horta, Sunnerhagen Per, Bargieri Daniel Youssef, Prudêncio Miguel, Quick Matthias, Cravo Pedro V, Lee Marcus C S, Fidock David A, Costa Fabio Trindade Maranhão

СтатьяResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

Artemisinin-based combination therapy (ACT) is the mainstay of effective treatment of Plasmodium falciparum malaria. However, the long-term utility of ACTs is imperiled by widespread partial artemisinin resistance in Southeast Asia and its recent emergence in parts of East Africa. This underscores the need to identify chemotypes with new modes of action (MoAs) to circumvent resistance to ACTs. In this study, we characterized the asexual blood stage antiplasmodial activity and resistance mechanisms of LDT-623, a 4-aminoquinoline (4-AQ). We also detected LDT-623 activity against multiple stages (liver schizonts, stage IV-V gametocytes, and ookinetes) of Plasmodium's life cycle, a feature unlike other 4-AQs such as chloroquine (CQ) and piperaquine (PPQ). Using heme fractionation profiling and drug uptake studies in PfCRT-containing proteoliposomes, we observed inhibition of hemozoin formation and PfCRT-mediated transport, which constitute characteristic features of 4-AQs' MoA. We also found minimal cross-resistance to LDT-623 in a panel of mutant pfcrt or pfmdr1 lines, but not the PfCRT F145I mutant that is highly resistant to PPQ resistance yet is very unfit. No P. falciparum parasites were recovered in an in vitro resistance selection study, suggesting a high barrier for resistance to emerge. Finally, a competitive growth assay comprising >50 barcoded parasite lines with mutated resistance mediators or major drug targets found no evidence of cross-resistance. Our findings support further exploration of this promising 4-AQ.

Для цитирования: Ferreira Letícia Tiburcio, Cassiano Gustavo Capatti, Alvarez Luis Carlos Salazar, Okombo John, Calit Juliana, Fontinha Diana, Gil-Iturbe Eva, Coyle Rachael, Andrade Carolina Horta, Sunnerhagen Per, Bargieri Daniel Youssef, Prudêncio Miguel, Quick Matthias, Cravo Pedro V, Lee Marcus C S, Fidock David A, Costa Fabio Trindade Maranhão. A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.. PLoS pathogens. 2024. DOI: 10.1371/journal.ppat.1012627.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.